• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research

Single or dual antiplatelet therapy after transcatheter aortic valve replacement: an updated systemic review and meta-analysis.
Conclusions: This meta-analysis suggests that compared with DAPT, SAPT after TAVR is more likely to lead to a decline of 30-day mortality along with the reduced risk of bleeding and no increased risk of stroke. However, more clinical data and evidence from randomized controlled trials are warranted to clarify the optimal post-TAVR antiplatelet strategy. PMID: 31019786 [PubMed]
Source: Journal of Thoracic Disease - April 27, 2019 Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research

Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.
CONCLUSIONS: Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF with ≥1 non-gender CHA2DS2VASc stroke risk factor(s). PMID: 30144419 [PubMed - as supplied by publisher]
Source: Chest - August 21, 2018 Category: Respiratory Medicine Authors: Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L Tags: Chest Source Type: research

Aspirin use for primary prevention in elderly patients.
Authors: Terrosu P Abstract The net clinical benefit of aspirin in primary prevention is uncertain as the reduction in occlusive events needs to be balanced against the increase in gastro-intestinal and cerebral bleedings. The meta-analysis of ATT (Anti Thrombotic Trialists) Collaboration in 2009 showed that aspirin therapy in primary prevention was associated with 12% reduction in cardio-vascular events, due mainly to a reduction in non-fatal myocardial infarction (0.18% vs 0.23% per year, p<0.0001). However, the benefit in term of coronary events was almost balanced by the increase in major bleedings. The ...
Source: Monaldi Archives for Chest Disease - July 7, 2016 Category: Respiratory Medicine Tags: Monaldi Arch Chest Dis Source Type: research

Time trends of aspirin and warfarin use on stroke and bleeding events in Chinese patients with new-onset atrial fibrillation.
Conclusion: Aspirin use increased amongst newly diagnosed Chinese AF patients with no relationship to the patient's stroke or bleeding risk. Warfarin use was very low. Given the healthcare burden of AF and its complications, our study has major implications for healthcare systems in non-Western countries, given the global burden of this common arrhythmia. PMID: 25501045 [PubMed - as supplied by publisher]
Source: Chest - December 11, 2014 Category: Respiratory Medicine Authors: Guo Y, Wang H, Tian Y, Wang Y, Lip GY Tags: Chest Source Type: research

Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: The AMADEUS study.
CONCLUSION We have developed and validated 2 novel composite scores for stroke/thromboembolism/ bleeding that offer good discriminatory and predictive performance. However, these composite risk scores did not perform better than the easier and more practical 'traditional' stroke and bleeding risk scores that are currently in use, which allow greater practically and more personalised balancing of risks. PMID: 24009027 [PubMed - as supplied by publisher]
Source: Chest - September 5, 2013 Category: Respiratory Medicine Authors: Lip GY, Lane DA, Buller H, Apostolakis S Tags: Chest Source Type: research